A phase II pharmacokinetic/pharmacogenetic (PK/PG) study using fixed-dose capecitabine in metastatic breast cancer (MBC)

Authors :: Elizabeth Garrett-Mayer
Nancy E. Davidson
Stanley P. Watkins
Michelle A. Rudek
L. Wright
D. K. Armstrong
Antonio C. Wolff
H. L. Mc Leod
Vered Stearns
John H. Fetting
Stacie Jeter
RM Connolly
Source :: Journal of Clinical Oncology. 29:1067-1067
Publication Year :: 2011
Publisher :: American Society of Clinical Oncology (ASCO), 2011.
Abstract: 1067 Background: The pro-drug capecitabine is approved in anthracycline- and paclitaxel-resistant MBC. However, GI/skin toxicity and wide interpatient PK variability occur despite body surface area...

Subjects :: Body surface area
Cancer Research
Anthracycline
business.industry
Pharmacology
medicine.disease
Fixed dose
Metastatic breast cancer
Capecitabine
Skin toxicity
Oncology
Pharmacokinetics
Medicine
business
Pharmacogenetics
medicine.drug

Tools